|Bid||84.98 x 400|
|Ask||85.03 x 500|
|Day's Range||84.80 - 85.27|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.97|
|Dividend & Yield||2.72 (3.27%)|
|1y Target Est||N/A|
Last week an FDA advisory panel voted unanimously (10-0) to approve CTL019 (tisagenlecleucel-T), a novel CAR-T cell immunotherapy developed by Novartis (NVS), for the treatment of children and young adults (ages 3 - 25) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). B-cell ALL is a form of Leukemia (i.e.
Aileron Therapeutics’ initial public offering was priced at $15 a share on June 28. You can be forgiven if you hadn’t heard of the cancer biotech’s IPO. Apart from a low media profile, the low-end IPO pricing was also a disappointment.
A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. "Their impact in the second half might limit Roche's chances of upgrading 2017 guidance," he said.